One must be extremely vigilant regarding the origin of peptides: unregulated channels (gray and black markets) carry major risks of impurities, and the vast majority of peptides (excluding GLP-1s for weight management) still lack robust clinical evidence in humans to guarantee their physical safety.

noli's read

Andrew Huberman’s warning about the quality of gray-market peptides is scientifically confirmed. An independent study published in April 2026 that analyzed more than 6,400 samples of peptides from outside official channels (including BPC-157 and TB-500) revealed that 41% to 71% of them failed basic quality criteria, with 15% presenting impurities or bacterial contamination. Furthermore, his assertion regarding the scientific robustness of GLP-1s is accurate, relying on rigorous randomized clinical trials (the STEP and SURMOUNT programs published in the New England Journal of Medicine). Conversely, the use of vitality or physical recovery molecules like BPC-157 relies on much weaker evidence. Reports from the U.S. regulatory agency (FDA) from July 2026 highlight a glaring lack of safety data in humans for these compounds, with the bulk of current evidence limited to animal models (such as the observational studies by Sikiric et al.). Favoring authorized channels and professional guidance therefore remains the only prudent approach to optimizing one’s vitality without risk.

the sources

1. 1Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS 2010
2. 2Wilding JPH et al. (STEP 1) 2021
3. 3Jastreboff AM et al. (SURMOUNT-1) 2022
4. 4Jastreboff AM et al. 2023
5. 5Wilding JPH et al. (STEP 1 extension) 2022